“Simple,” “Accurate,” and “Effective” were the words ADA presenters used to describe Dexcom G6, a new continuous glucose monitor (CGM) system.
The introduction of the new Dexcom G6 took place at the ADA 78th Scientific Sessions in the Orange County Convention Center in Orlando, Florida, where attendees from around the world came to learn and share ideas about the latest findings in diabetes. Hands-on demonstrations, features and technology advancements, trial data, patient experience, and performance regarding the Dexcom G6 CGM system wrapped up the agenda presented during an entire hour.
But now, let’s get a closer look at the Dexcom G6. If you as a patient or as a clinician are afraid of needles there is no problem since there is no longer need to fingerstick or calibrate to make therapy adjustments. Like Dexcom G5, the new device has an overall MARD of 9% with the advantage of no calibration and giving consistent readings even when glucose levels are rapidly going up and down. As with the past generation, the new device is also indicated for patients ages 2 years and older, which empowers parents and pediatricians to closely track the children’s therapy. New alerts options have been added to this new system: first, the “Urgent Low Soon” alert, which provides a 20-minute advance warning in case of a severe hypoglycemic event. This feature could be an advantage for those patients that experience hypoglycemia unawareness.
There is also a new option of customizing alerts in a 24-hour period. Now the patient can divide the alerts in 12-hour periods, day and night, and have a better perception and flexibility on when you are going low or high. Within the new components that have been added to this CGM system, they have presented the “Easy Auto Applicator,” a one-touch device that places the sensor just beneath the skin, a “Discreet and low profile device” and a “10-day sensor wear.” These characteristics make the Dexcom G6 28% lower profile, making the sensor not visible under clothing, with a 43% longer wear than the last generation.
Outcomes of the I HART CGM, COMISAIR, GOLD, and The DIAMOND studies were briefly discussed. The latter one, a randomized controlled trial that compares the efficacy of multiple daily injections (MDI) regimen augmented by CGM vs. self-monitoring glucose, was a point of specific interest. Study results have shown that patients using CGM have experienced a significant reduction in HbA1c regardless of education level, math ability, and age. High rates of adherence at week 24, and a significant increase of time spent in range from baseline, can be translated in a reduction of time spent in hypo- and hyperglycemic events.
Dexcom Clarity, a method to share the CGM data with the patient clinic, was another topic of discussion. The software is intended for the use of healthcare professionals to assist them in reviews, analysis, and evaluation of historical CGM data, helping them to better manage their patient’s therapies. Technology is constantly changing and with this new CGM system, Dexcom is trying to stay ahead of everything, and of course of Freestyle Libre, a flash glucose monitoring system that shares many characteristics with the G6. See you all next year in San Francisco.
- CGM use has been proven to both reduce HbA1c and decrease risk of hypoglycemia regardless of delivery method.
- If the patient’s glucose alerts and readings from the Dexcom G6 do not match symptoms, the use of a glucose meter to make therapy adjustments is recommended.
- Dexcom Clarity provides to the healthcare professional a very powerful tool to help the patients with glycemic management.
- Leone, J. Leach, R. Paul Wadwa. Introducing The New Dexcom G6, ADA 78th Scientific Sessions, Saturday, June 23, 2018.
ADA 78th Scientific Sessions, Saturday, June 23, 2018, booth #1237
American Diabetes Association 78th Scientific Sessions, Orlando Florida
Kennen Munoz Munoz, Pharm. D. Candidate 2019, LECOM School of Pharmacy